Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma

PURPOSE: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct glioma molecular subtype for which no effective molecularly-directed therapy exists. Low-grade gliomas, which are 80–90% IDH mutant, have high RNA levels of the cell surface Notch ligand DLL3. We sought to determine DLL3 expressio...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Spino, Marissa, Kurz, Sylvia C., Chiriboga, Luis, Serrano, Jonathan, Zeck, Briana, Sen, Namita, Patel, Seema, Shen, Guomiao, Vasudevaraja, Varshini, Suryadevara, Carter M., Frenster, Joshua, Tateishi, Kensuke, Wakimoto, Hiroaki, Jain, Rajan, Riina, Howard A., Nicolaides, Theodore P., Sulman, Erik P., Cahill, Daniel P., Golfinos, John G., Isse, Kumiko, Saunders, Laura R., Zagzag, David, Placantonakis, Dimitris, Snuderl, Matija, Chi, Andrew S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7365589/
https://ncbi.nlm.nih.gov/pubmed/30397180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2312
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg